ACUTE MYELOID LEUKEMIA MARKET OUTLOOK, 2034 | COMPREHENSIVE INSIGHTS INTO EVOLVING MARKET DYNAMICS, EPIDEMIOLOGY TRENDS, GROWTH OPPORTUNITIES, EMERGING THERAPIES, AND LEADING COMPANIES

The Acute Myeloid Leukemia market presents a promising outlook, with numerous emerging therapies at different stages of clinical development. The overall dynamics of the market are expected to evolve in the coming years, particularly with the anticipated launch of targeted therapies. Key candidates include Dociparstat Sodium (Chimerix), Uproleselan (GlycoMimetics Incorporated), Crenolanib besylate (Arog Pharmaceuticals), JSP191 (Jasper Therapeutics), among others.

DelveInsight's report, "Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast 2034," provides a comprehensive analysis of the disease, including historical and projected epidemiology, as well as insights into the market size, share, trends, and growth opportunities across the seven major markets (7MM) - the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

The report examines emerging drugs, current treatment practices, the market share of individual therapies, and market size forecasts from 2020 to 2034. It also assesses current treatment algorithms, identifies key drivers and barriers to market growth, and addresses unmet medical needs to highlight opportunities and evaluate the market's potential.

Download sample report @ https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia, is a complex blood cancer marked by the abnormal proliferation of myeloid blasts in the blood, bone marrow, and various tissues. This disease can spread beyond the bone marrow and blood, impacting areas such as lymph nodes, the brain, skin, and other organs.

AML is the most common form of leukemia in adults, accounting for approximately 80% of cases. It is characterized by ineffective erythropoiesis and bone marrow failure resulting from the uncontrolled growth of immature "blast cells" in the blood and bone marrow. The disease primarily affects older individuals, with a median age of diagnosis around 67 years. Each patient typically presents unique chromosomal abnormalities, which tend to increase in prevalence with age.

Read more about acute myeloid leukemia market report @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia Market Key Facts
In 2023, the United States held the largest market share for Acute Myeloid Leukemia (AML), outpacing the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The total number of incident AML cases across the seven major markets (7MM) in 2023 was approximately 43,500, with the highest incidence reported in the United States. While most newly diagnosed patients receiving frontline therapy achieve remission, 30-40% may experience a relapse.

The treatment landscape for AML has remained largely unchanged for nearly five decades. Currently approved drugs for frontline and relapse/refractory settings include VYXEOS (Jazz Pharmaceuticals), RYDAPT (Novartis), ONUREG (BMS), DAURISMO (Pfizer), TIBSOVO (Agios Pharma), VENCLEXTA (AbbVie), IDHIFA (BMS), XOSPATA (Astellas Pharma), and VANFLYTA (Daiichi Sankyo), among others.

Key players such as Arog Pharmaceuticals (Crenolanib), Actinium Pharmaceutical (Iomab-B), Astex Pharmaceuticals (ASTX030), Syndax (Revumenib), SELLAS Life Sciences (SLS009), and Johnson & Johnson Innovative Medicine (JNJ-75276617) are actively developing therapies for AML. The KMT2A rearrangement occurs in up to 15% of children and adults with acute leukemias and about 80% of infants with acute lymphoblastic leukemia. The NPM1 mutation is more prevalent, affecting up to 30% of AML patients.

Currently, there are no approved targeted therapies for KMT2A-related disease. However, menin inhibitors in clinical development have shown promising complete remission (CR) and complete remission with partial hematologic recovery (CRh) rates in populations with KMT2A rearrangements or NPM1 mutations, such as Syndax's Revumenib (23% in KMT2A rearrangement), Kura's Ziftomenib (35% in NPM1m), and Janssen's JNJ-75276617 (21% in KMT2Ar/NPM1m populations). Revumenib is the only drug with Phase II data demonstrating high remission rates and a predictable safety profile in both pediatric and adult patients with KMT2A rearrangement AML. Syndax anticipates an FDA decision on Revumenib for KMT2Ar acute leukemia by December 26, 2024. Once regulatory clearance is received, Syndax is prepared to launch Revumenib, with plans already in place to cover over 90% of insured lives, including Part D and commercial plans.

In February 2024, Gilead Sciences discontinued the Phase III ENHANCE-3 study, and the US FDA placed all magrolimab studies in myelodysplastic syndromes (MDS) and AML, including related expanded access programs, on full clinical hold. This decision was based on interim analysis results indicating futility and an increased risk of death, leading the company to cease development of the treatment for hematologic cancers.

The growth of the AML market is expected to be driven primarily by the introduction of novel therapies with improved clinical profiles, increased market penetration of targeted therapies, heightened research and development efforts, a deeper understanding of the disease, and rising AML incidence alongside imminent drug launches. However, challenges such as high therapy costs, toxic treatment options, difficulties in designing clinical trials, and low survival rates may impede market growth.

Visit the link to download free sample report @ https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia Market

The primary goal of treatment for Acute Myeloid Leukemia (AML) is to achieve remission. Current conventional therapies rely heavily on intensive chemotherapy-based induction and consolidation, along with hematopoietic stem cell transplantation. However, not all patients are suitable candidates for this intensive approach, which can be physically and mentally taxing, especially for older individuals. Typically, the standard treatment involves a combination of cytarabine and an anthracycline (such as daunorubicin), a regimen that has been the cornerstone of AML treatment for decades, particularly among younger, healthier patients. Allogeneic stem cell transplantation remains a potentially curative option for those in remission.

There are several established targeted therapies for AML, such as RYDAPT and XOSPATA, which focus on FLT3 mutations found in about 30% of AML patients. TIBSOVO and IDHIFA are used for patients with IDH1 and IDH2 mutations, respectively. VENCLEXTA, a BCL-2 inhibitor, is combined with hypomethylating agents or low-dose cytarabine for patients who are not candidates for intensive chemotherapy.

The market is currently witnessing a surge in novel therapies, including targeted treatments, immunotherapies, and cell-based therapies. Ongoing research is exploring the use of monoclonal antibodies, CAR-T cell therapy, and checkpoint inhibitors in the context of AML. The market for AML treatments is expected to expand significantly in the coming years, with pharmaceutical companies such as Arog Pharmaceuticals, Actinium Pharmaceutical, Astex Pharmaceuticals, Syndax, SELLAS Life Sciences, and Johnson & Johnson Innovative Medicine actively developing and marketing new therapies.

Among the seven major markets (7MM), the United States represents the largest market for AML. Within the EU4 and the UK, Germany had the highest market size in 2023, while Spain had the lowest. There is currently no approved targeted therapy for the NPM1-mutant AML subgroup, which represents a significant unmet need, as it accounts for approximately 30% of new AML cases annually. In April 2024, Ziftomenib became the first investigational treatment to receive breakthrough therapy designation for NPM1-mutant AML.

Syndax has established a robust clinical development plan for Revumenib, aiming to position it as a treatment option for acute leukemias with mutant NPM1 and KMT2A rearrangements. This plan extends beyond initial indications for relapsed or refractory AML, as ongoing trials with Revumenib in combination with standard care may support its use in frontline settings, relapse, refractory cases, and post-transplant maintenance.

Visit our report @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia Epidemiology Assessment

The epidemiology section offers insights into historical, current, and projected trends in the seven major markets (7MM) from 2020 to 2034. It identifies the factors influencing these trends by reviewing a variety of studies and research. Additionally, this section includes a comprehensive analysis of the diagnosed and prevalent patient population, future projections, and perspectives from key opinion leaders.

The Report Covers the Acute Myeloid Leukemia (AML) Epidemiology, Segmented by -
Total Incident Cases of Acute Myeloid Leukemia in the 7MM [2020-2034]
Gender-specific Cases of Acute Myeloid Leukemia in the 7MM [2020-2034]
Age-specific Cases of Acute Myeloid Leukemia in the 7MM [2020-2034]
Mutation-specific Cases of Acute Myeloid Leukemia in the 7MM [2020-2034]

Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities

The drug uptake section analyzes the adoption rates of recently launched or soon-to-be-launched therapies in the Acute Myeloid Leukemia market. This includes an assessment of drug uptake, patient therapy choices, and sales performance for each treatment. Additionally, the therapeutics assessment examines which drugs are experiencing the fastest uptake and explores the factors driving their increased use. It also compares the drugs based on their market share.

Furthermore, the report addresses pipeline development activities in the Acute Myeloid Leukemia space. It provides valuable insights into various therapeutic candidates at different stages of development and highlights the key companies working on targeted therapies. The analysis includes recent developments such as collaborations, acquisitions, mergers, licensing agreements, and other relevant information about emerging treatments.

Learn How the Acute Myeloid Leukemia Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia Therapeutics Analysis

Acute Myeloid Leukemia (AML) faces several significant unmet needs. There is an urgent demand for more effective and less toxic treatments, particularly since many AML patients are not eligible for standard induction therapy. The disease is also characterized by high rates of relapse and refractory cases. Furthermore, there is a considerable lack of attention to improving the quality of life for patients suffering from disease-related symptoms and therapy-induced toxicities.

The therapeutics landscape is highly dynamic, driven by these unmet needs, with a strong pipeline of drugs in clinical development expected to stimulate market growth in the near future. Over 260 key companies are currently developing therapies for AML, with Gamida Cell leading the way, having its drug candidates in the most advanced stages of clinical development.

The Leading Companies in the Acute Myeloid Leukemia (AML) Therapeutics Market Include:

Jazz Pharmaceuticals, AbbVie, Arog Pharmaceuticals, Takeda, Immunomedics, Inc., Agios Pharmaceuticals, Delta-Fly Pharma, Astellas Pharma, Clear Creek Bio Inc., BerGenBio ASA, Pfizer, MacroGenics, Novartis Oncology, Syndax Pharmaceuticals, AstraZeneca, Chimerix, CellCentric Ltd., Daiichi Sankyo, Forma Therapeutics, Curis, Inc., Rafael Pharmaceuticals Inc., GlycoMimetics Incorporated, Biosight Ltd., Actinium Pharmaceuticals, Astex Pharmaceuticals, Inc., Sellas Life Sciences Group, NexImmune Inc., and many others.

Learn more about the leading players in the acute myeloid leukemia market @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Myeloid Leukemia (AML) Drugs Covered in the Report Include:
Omidubicel: Gamida Cell
Uproleselan: GlycoMimetics
ALT 803: ImmunityBio
BPX-501: Bellicum Pharmaceuticals
Dociparstat Sodium (Chimerix
Crenolanib besylate: Arog pharmaceuticals
JSP191: Jasper therapeutics
And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Key Insights
2. Executive Summary
3. Acute Myeloid Leukemia Competitive Intelligence Analysis
4. Acute Myeloid Leukemia Market Overview at a Glance
5. Acute Myeloid Leukemia Disease Background and Overview
6. Acute Myeloid Leukemia Patient Journey
7. Acute Myeloid Leukemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Myeloid Leukemia Unmet Needs
10. Key Endpoints of Acute Myeloid Leukemia Treatment
11. Acute Myeloid Leukemia Marketed Products
12. Acute Myeloid Leukemia Emerging Drugs and Latest Therapeutic Advances
13. Acute Myeloid Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Acute Myeloid Leukemia Market Outlook (In US, EU5, and Japan)
16. Acute Myeloid Leukemia Access and Reimbursement Overview
17. KOL Views on the Acute Myeloid Leukemia Market
18. Acute Myeloid Leukemia Market Drivers
19. Acute Myeloid Leukemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Contact Us:
Kritika Rehani
krehani@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.